| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 4/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
GEN Stock Overview
Genomed Spólka Akcyjna provides DNA analysis and congenital diseases diagnostic services in Poland.
Genomed Spólka Akcyjna Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | zł36.00 |
| 52 Week High | zł50.00 |
| 52 Week Low | zł30.20 |
| Beta | 0.049 |
| 1 Month Change | -2.70% |
| 3 Month Change | 1.12% |
| 1 Year Change | -1.64% |
| 3 Year Change | 73.08% |
| 5 Year Change | 68.54% |
| Change since IPO | 28.57% |
Recent News & Updates
Would Genomed Spólka Akcyjna (WSE:GEN) Be Valuable To Income Investors?
Today we'll take a closer look at Genomed Spólka Akcyjna ( WSE:GEN ) from a dividend investor's perspective. Owning a...
Shareholder Returns
| GEN | PL Biotechs | PL Market | |
|---|---|---|---|
| 7D | 0% | -1.7% | -1.2% |
| 1Y | -1.6% | -40.0% | -27.0% |
Return vs Industry: GEN exceeded the Polish Biotechs industry which returned -38.4% over the past year.
Return vs Market: GEN exceeded the Polish Market which returned -28.3% over the past year.
Price Volatility
| GEN volatility | |
|---|---|
| GEN Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 8.6% |
| Market Average Movement | 7.7% |
| 10% most volatile stocks in PL Market | 14.7% |
| 10% least volatile stocks in PL Market | 5.1% |
Stable Share Price: Insufficient data to determine GEN's volatility over the past 3 months.
Volatility Over Time: Insufficient data to determine GEN's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | 42 | Anna Boguszewska-Chachulska | https://www.genomed.pl |
Genomed Spólka Akcyjna provides DNA analysis and congenital diseases diagnostic services in Poland. It develops molecular diagnostics based on DNA sequencing for the application of prophylactics and treatment, such as replacement or gene therapy. The company also offers the analysis of mutations responsible for congenital diseases in approximately 150 genes; and next-generation sequencing technology.
Genomed Spólka Akcyjna Fundamentals Summary
| GEN fundamental statistics | |
|---|---|
| Market Cap | zł47.57m |
| Earnings (TTM) | zł821.55k |
| Revenue (TTM) | zł19.90m |
57.9x
P/E Ratio2.4x
P/S RatioIs GEN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| GEN income statement (TTM) | |
|---|---|
| Revenue | zł0 |
| Cost of Revenue | zł0 |
| Gross Profit | zł0 |
| Other Expenses | zł0 |
| Earnings | zł0 |
Last Reported Earnings
Mar 31, 2022
Next Earnings Date
May 23, 2022
| Earnings per share (EPS) | 0.62 |
| Gross Margin | 63.18% |
| Net Profit Margin | 4.13% |
| Debt/Equity Ratio | 5.2% |
How did GEN perform over the long term?
See historical performance and comparisonValuation
Is Genomed Spólka Akcyjna undervalued compared to its fair value and its price relative to the market?
Valuation Score
0/6Valuation Score 0/6
Below Fair Value
Significantly Below Fair Value
PE vs Industry
PE vs Market
PEG Ratio
PB vs Industry
57.9x
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: GEN (PLN36) is trading above our estimate of fair value (PLN26.78)
Significantly Below Fair Value: GEN is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: GEN is poor value based on its PE Ratio (57.9x) compared to the Polish Biotechs industry average (41.8x).
PE vs Market: GEN is poor value based on its PE Ratio (57.9x) compared to the Polish market (10.3x).
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate GEN's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: GEN is overvalued based on its PB Ratio (5.7x) compared to the PL Biotechs industry average (4.7x).
Future Growth
How is Genomed Spólka Akcyjna forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Future Growth Score
0/6Future Growth Score 0/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Future ROE
42.3%
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Genomed Spólka Akcyjna has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
Past Performance
How has Genomed Spólka Akcyjna performed over the past 5 years?
Past Performance Score
4/6Past Performance Score 4/6
Quality Earnings
Growing Profit Margin
Earnings Trend
Accelerating Growth
Earnings vs Industry
High ROE
-16.7%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: GEN has high quality earnings.
Growing Profit Margin: GEN's current net profit margins (4.1%) are higher than last year (2.2%).
Past Earnings Growth Analysis
Earnings Trend: GEN's earnings have declined by 16.7% per year over the past 5 years.
Accelerating Growth: GEN's earnings growth over the past year (99.3%) exceeds its 5-year average (-16.7% per year).
Earnings vs Industry: GEN earnings growth over the past year (99.3%) exceeded the Biotechs industry -6.2%.
Return on Equity
High ROE: GEN's Return on Equity (9.8%) is considered low.
Financial Health
How is Genomed Spólka Akcyjna's financial position?
Financial Health Score
5/6Financial Health Score 5/6
Short Term Liabilities
Long Term Liabilities
Debt Level
Reducing Debt
Debt Coverage
Interest Coverage
Financial Position Analysis
Short Term Liabilities: GEN's short term assets (PLN8.0M) exceed its short term liabilities (PLN1.4M).
Long Term Liabilities: GEN's short term assets (PLN8.0M) exceed its long term liabilities (PLN599.5K).
Debt to Equity History and Analysis
Debt Level: GEN has more cash than its total debt.
Reducing Debt: Insufficient data to determine if GEN's debt to equity ratio has reduced over the past 5 years.
Debt Coverage: GEN's debt is well covered by operating cash flow (397.6%).
Interest Coverage: GEN's interest payments on its debt are well covered by EBIT (423x coverage).
Balance Sheet
Dividend
What is Genomed Spólka Akcyjna current dividend yield, its reliability and sustainability?
Dividend Score
0/6Dividend Score 0/6
Notable Dividend
High Dividend
Stable Dividend
Growing Dividend
Earnings Coverage
Future Dividend Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate GEN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate GEN's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if GEN's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if GEN's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: GEN is not paying a notable dividend for the Polish market.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as GEN has not reported any payouts.
Discover strong dividend paying companies
Management
How experienced are the management team and are they aligned to shareholders interests?
CEO
Anna Boguszewska-Chachulska
no data
Tenure
Dr. Hab. Anna Boguszewska-Chachulska, Ph.D. is a Co-founder of Genomed Spólka Akcyjna and has been its Chief Executive Officer since 2013. Dr. Hab. Boguszewska-Chachulska also serves as President of the Ma...
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Ownership Breakdown
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Top Shareholders
Company Information
Genomed Spólka Akcyjna's employee growth, exchange listings and data sources
Key Information
- Name: Genomed Spólka Akcyjna
- Ticker: GEN
- Exchange: WSE
- Founded: 2007
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: zł47.567m
- Shares outstanding: 1.32m
- Website: https://www.genomed.pl
Number of Employees
Location
- Genomed Spólka Akcyjna
- ul. Ponczowa 12
- Warsaw
- 02-971
- Poland
Listings
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2022/05/20 00:00 |
| End of Day Share Price | 2022/05/12 00:00 |
| Earnings | 2022/03/31 |
| Annual Earnings | 2021/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.